Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

NanoString Technologies, Inc. (NSTG)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
14.43-0.20 (-1.37%)
At close: 04:00PM EDT
14.43 0.00 (0.00%)
After hours: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Williams %R

Williams %R

Previous Close14.63
Open14.65
Bid14.00 x 1000
Ask16.66 x 1800
Day's Range13.98 - 14.68
52 Week Range11.12 - 62.34
Volume551,366
Avg. Volume815,069
Market Cap670.91M
Beta (5Y Monthly)1.91
PE Ratio (TTM)N/A
EPS (TTM)-2.78
Earnings DateNov 07, 2022 - Nov 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for NSTG

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • NanoString Technologies, Inc.
    Analyst Report: Bio-Rad Laboratories, Inc.Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (60% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the United States (40% of 2020 sales), Europe (34%), and Asia (21%), with Canada and Latin America accounting for the bulk of the remaining 5%. Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
    Rating
    Fair Value
    Economic Moat
    last yearMorningstar
View more
Advertisement
Advertisement